If you do not find what you are looking for try searching with a different term or contact us.
McNamara, K. F., Biondi, B. E., Hernández-Ramírez, R. U., Taweh, N., Grimshaw, A. A., & Springer, S. A. (2021). A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes. Open forum infectious diseases, 8(8), ofab289. https://doi.org/10.1093/ofid/ofab289
Springer, S. A., Merluzzi, A. P., & Del Rio, C. (2020). Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics: A Report From the National Academies of Sciences, Engineering, and Medicine. JAMA, 324(1), 37–38. https://doi.org/10.1001/jama.2020.2559
This manual assists behavioral health professionals who treat people living with substance use disorders in understanding the implications of a hepatitis diagnosis. It discusses screening and referrals, and explains how to evaluate a program’s hepatitis practices. Access the literary review.
This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for substance use disorder (SUD) treatment providers to effectively engage people with HIV in SUD treatment.
This CDC resource highlights the critical role of Syringe Services Programs (SSPs) in preventing the spread of infectious diseases, such as hepatitis C and HIV, among people who inject drugs. SSPs offer various services, including access to sterile syringes, testing, counseling, and referrals to substance use disorder treatment, significantly reducing the risk of infections and overdose deaths. Research indicates that SSPs are safe, effective, and associated with positive outcomes, including increased entry into drug treatment and reduced drug use. Additionally, SSPs collaborate with law enforcement to provide naloxone and safe needle disposal, contributing to community safety.222
This website from the Agency for Healthcare Research and Quality (AHRQ) underscores the heightened risk of infectious diseases, such as hepatitis C, hepatitis B, HIV, and other sexually transmitted diseases, among individuals with opioid use disorder (OUD).
This resource, from the CDC, highlights the intersection of the opioid crisis and infectious diseases among people who inject drugs (PWID), including viral hepatitis, HIV, and bacterial and fungal infections. It emphasizes the importance of evidence-based prevention programs, such as syringe services programs (SSPs), in providing comprehensive services like sterile syringe access, testing, vaccination, and linkage to care. The CDC’s efforts focus on implementing these programs to mitigate the spread of infections and offer support and resources for individuals affected by substance use disorders.
This CDC resource discusses the safety and effectiveness of Syringe services programs (SSPs) which are proven and effective community-based prevention programs that can provide a range of services and protect the public and first responders by facilitating the safe disposal of used needles and syringes.